Evidence map›Paper›PMID 42357806›Full record

ArticleAPMIS : acta pathologica, microbiologica, et immunologica Scandinavica2026

Immune Cell Composition and Prognosis in Node-Positive, Irradiated Breast Cancer Patients in the DBCG-IMN2 Study.

Demet Özcan, Anders Winther Mølby Nielsen, Patricia Switten Nielsen, Jan Alsner, Lise Bech Jellesmark Thorsen, Jens Overgaard, Birgitte Vrou Offersen, Trine Tramm

Abstract read
In one paragraph

Article in APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Demet ÖzcanDepartment of Pathology, Aarhus University Hospital, Aarhus, Denmark.ORCID https://orcid.org/0000-0001-6537-0035
Anders Winther Mølby NielsenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Patricia Switten NielsenDepartment of Pathology, Aarhus University Hospital, Aarhus, Denmark.ORCID https://orcid.org/0000-0002-7859-6321
Jan AlsnerDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Lise Bech Jellesmark ThorsenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Jens OvergaardDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Birgitte Vrou OffersenDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Trine TrammDepartment of Pathology, Aarhus University Hospital, Aarhus, Denmark.

Funding

Agnes og Poul Friis FondDansk Kræftforsknings Fond DKF-2021-88 - (699)Kræftens Bekæmpelse R148-A10067-16-S46Kræftens Bekæmpelse RR269-A15563
6 · The paper itself

Abstract

High levels of tumor-infiltrating lymphocytes (TILs) are associated with improved survival after radiotherapy in breast cancer (BC) patients, particularly in estrogen receptor (ER)-negative disease. This study investigated the prognostic relevance of immune cell subsets in irradiated patients. Node-positive patients (N = 1307) from the Danish Breast Cancer Group internal mammary node (IMN)2 study were included, in which IMN irradiation (IMNI) was allocated by laterality. Tissue microarrays were stained with multiplex immunohistochemistry for CD8+, CD4+, and FOXP3+ T-cells, CD68+ macrophages, and CD11c+ dendritic cells. Digital image analysis quantified immune infiltration across spatial compartments. Prognostic associations with distant recurrence, breast cancer-specific mortality, and overall mortality (OM) were assessed using multivariable flexible parametric survival models, including ER-stratified analyses. T-cell infiltration demonstrated a strong inverse association with OM, with 12-year OM-risk decreasing from 42% in tumors with lowest CD8+ infiltration to 27% in those with highest (HR 0.52, 95% CI (0.36-0.76)). The association was strongest in the ER-negative subgroup. In ER-positive disease, prognostic benefit was observed at low-to-moderate infiltration. CD68+ and CD11c+ infiltration correlated with improved outcomes, but with weaker effects. Immune markers were not predictive of IMNI benefit. These findings demonstrate that T-cell subsets are strong prognostic markers in irradiated BC patients, especially in ER-negative disease.

Indexed as

Breast NeoplasmsLymphocytes, Tumor-InfiltratingAdultAgedAntigens, CDAntigens, Differentiation, MyelomonocyticCD11c AntigenCD68 MoleculeCD8-Positive T-LymphocytesDendritic CellsDenmarkFemaleForkhead Transcription FactorsHumansImmunohistochemistryMacrophagesAntigens, CDAntigens, Differentiation, MyelomonocyticCD11c AntigenCD68 antigen, humanCD68 MoleculeForkhead Transcription FactorsFOXP3 protein, humanbreast cancerdigital image analysisimmune cellsradiotherapysurvival

Identifiers

PMID42357806
PMCPMC13305145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.